List of bibliographic references
Number of relevant bibliographic references: 4.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Genotype |
| 3 | Adult |
| 3 | Drug Therapy, Combination |
| 3 | Female |
| 3 | Hepatitis C, Chronic (drug therapy) |
| 3 | Humans |
| 3 | Male |
| 3 | Middle Aged |
| 3 | Treatment Outcome |
| 2 | Aged |
| 2 | Antiviral Agents (administration & dosage) |
| 2 | Antiviral Agents (therapeutic use) |
| 2 | Drug Administration Schedule |
| 2 | Hepacivirus (genetics) |
| 2 | Hepatitis C, Chronic (virology) |
| 2 | Imidazoles (administration & dosage) |
| 2 | RNA, Viral (blood) |
| 2 | Young Adult |
| 1 | Administration, Oral |
| 1 | Adolescent |
| 1 | Aged, 80 and over |
| 1 | Antiviral |
| 1 | Antiviral Agents (adverse effects) |
| 1 | Asunaprevir |
| 1 | Chemotherapy |
| 1 | Daclatasvir |
| 1 | Dose-Response Relationship, Drug |
| 1 | Double-Blind Method |
| 1 | Drug combination |
| 1 | Fatigue (epidemiology) |
| 1 | Headache (epidemiology) |
| 1 | Hepacivirus (classification) |
| 1 | Hepacivirus (isolation & purification) |
| 1 | Hepatitis C virus |
| 1 | Hepatitis C, Chronic (blood) |
| 1 | Hepatitis C, Chronic (classification) |
| 1 | Hepatitis C, Chronic (genetics) |
| 1 | Human |
| 1 | Imidazoles (therapeutic use) |
| 1 | Incidence |
| 1 | Interferon-alpha (administration & dosage) |
| 1 | Interferon-alpha (adverse effects) |
| 1 | Interferon-alpha (therapeutic use) |
| 1 | Isoquinolines (administration & dosage) |
| 1 | Isoquinolines (therapeutic use) |
| 1 | Medicine |
| 1 | Nausea (epidemiology) |
| 1 | Oligopeptides (administration & dosage) |
| 1 | Oligopeptides (adverse effects) |
| 1 | Oligopeptides (therapeutic use) |
| 1 | Oral administration |
| 1 | Phase III trial |
| 1 | Polyethylene Glycols (administration & dosage) |
| 1 | Polyethylene Glycols (adverse effects) |
| 1 | Polyethylene Glycols (therapeutic use) |
| 1 | Recombinant Proteins (administration & dosage) |
| 1 | Recombinant Proteins (adverse effects) |
| 1 | Recombinant Proteins (therapeutic use) |
| 1 | Remission Induction |
| 1 | Ribavirin (administration & dosage) |
| 1 | Ribavirin (adverse effects) |
| 1 | Ribavirin (therapeutic use) |
| 1 | Sulfonamides (administration & dosage) |
| 1 | Sulfonamides (therapeutic use) |
| 1 | Typing |
| 1 | Viral Load (drug effects) |
| 1 | Viral hepatitis C |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "William Sievert"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "William Sievert" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= William Sievert
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
